FibroGen (NASDAQ:FGEN) Now Covered by StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of FibroGen (NASDAQ:FGEN) in a note issued to investors on Wednesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, William Blair reiterated a “market perform” rating on shares of FibroGen in a research note on Monday, June 3rd.

FibroGen Stock Up 6.8 %

Shares of NASDAQ:FGEN opened at $0.42 on Wednesday. FibroGen has a 52-week low of $0.33 and a 52-week high of $2.93. The stock has a market cap of $42.11 million, a price-to-earnings ratio of -0.17 and a beta of 0.69. The business has a 50-day moving average price of $0.64 and a 200-day moving average price of $1.17.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.09. The business had revenue of $50.64 million during the quarter, compared to analysts’ expectations of $33.00 million. During the same period last year, the company earned ($0.65) earnings per share. As a group, equities analysts anticipate that FibroGen will post -0.91 EPS for the current fiscal year.

Institutional Investors Weigh In On FibroGen

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Armistice Capital LLC lifted its stake in shares of FibroGen by 23.7% in the 4th quarter. Armistice Capital LLC now owns 9,764,000 shares of the biopharmaceutical company’s stock valued at $8,654,000 after purchasing an additional 1,872,000 shares during the period. Acadian Asset Management LLC raised its position in shares of FibroGen by 34.4% in the second quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock worth $2,997,000 after acquiring an additional 860,854 shares during the period. AQR Capital Management LLC raised its position in shares of FibroGen by 139.6% in the second quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock worth $1,179,000 after acquiring an additional 769,586 shares during the period. Pennant Investors LP purchased a new stake in shares of FibroGen during the 4th quarter worth about $681,000. Finally, XTX Topco Ltd acquired a new stake in shares of FibroGen during the 2nd quarter valued at about $424,000. Institutional investors and hedge funds own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.